CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)42 enrolled

Overview

This phase I trial is studying the side effects, best way to give, and best dose of CCI-779 and EKB-569 in treating patients with advanced solid tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. EKB-569 may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving CCI-779 together with EKB-569 may kill more tumor cells.

OBJECTIVES: I. Determine the maximum tolerated dose of the combination of CCI-779 and EKB-569 in patients with advanced solid tumors. II. Determine the toxicity of this regimen in these patients. III. Determine the response rate in patients treated with this regimen. OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 3 treatment groups. Group I: Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21. Cohorts of 3-6 patients receive escalating doses of EKB-569 and CCI-779 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Group II: Patients receive oral EKB-569 at the MTD on days 4-28 of course 1 and days 1-28 of all subsequent courses and CCI-779 at the MTD on days 1-3 and 15-17. Group III: Patients receive EKB-569 at the MTD as in group I and oral CCI-779 at the MTD on days 7-9 and 19-21 of course 1 and days 1-3 and 15-17 of all subsequent courses. In all groups, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 30-42 patients (18-30 for group I, 6 for group II, and 6 for group III) will be accrued for this study within 1.35-1.75 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

pelitinibDRUG

temsirolimusDRUG

Given PO

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed unresectable solid tumor for which there is no known standard therapy that is potentially curative or capable of extending life expectancy * No CNS metastases * Performance status - ECOG 0-2 * At least 12 weeks * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 10 g/dL * Bilirubin normal * AST ≤ 3 times upper limit of normal (ULN) (5 times ULN if liver involvement) * Creatinine ≤ 1.5 times ULN * No New York Heart Association class III or IV heart disease * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study participation * Fasting cholesterol \< 350 mg/dL * Fasting triglycerides \< 400 mg/dL * No uncontrolled infection * No seizure disorder * More than 4 weeks since prior immunotherapy * More than 4 weeks since prior biologic therapy * No concurrent immunotherapy * No concurrent prophylactic colony-stimulating factor therapy * More than 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered * No other concurrent chemotherapy * No concurrent oral contraceptives * More than 4 weeks since prior radiotherapy * No prior radiotherapy to \> 30% of bone marrow * No concurrent radiotherapy * More than 7 days since prior CYP3A4 inducers * No prior mTOR-targeting agents * No prior epidermal growth factor receptor-targeting agents * No concurrent antiretroviral therapy that induces or inhibits CYP3A4 for HIV-positive patients * No other concurrent investigational agents * No concurrent warfarin

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Maximum tolerated dose (MTD) defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients

Time frame: Up to 28 days

Number and severity of all adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0

Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.

Time frame: Up to 30 days after last dose of study treatment

Secondary Outcomes

Best response according to the Response Evaluation Criteria in Solid Tumors (RECIST)

Time frame: Time from the start of the treatment until disease progression/recurrence, assessed up to 3 years

Time until any treatment related toxicity

Time frame: Up to 3 years

Time until treatment related grade 3+ toxicity

Time frame: Up to 3 years

Time until hematologic nadirs (white blood cells [WBC], absolute neutrophil count [ANC], platelets)

Time frame: Up to 3 years

Time to progression

Time frame: Up to 3 years

Time to treatment failure

Time frame: Time from registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.